Suppr超能文献

熵:年轻直肠癌患者放化疗治疗的单中心分析

E_N_T_R_O_P_Y: Monocentric analysis of rectal cancer radio-chemotherapy treatment in patients of young age.

作者信息

Meldolesi E, Nicolì A, Dinapoli N, Chiloiro G, Romano A, Menghi R, Persiani R, Pacelli F, Coco C, Ratto C, Manfrida S, Boldrini L, Corvari B, Gambacorta M A

机构信息

Department of Diagnostic Imaging, Radiation Oncology and Haematology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Department of Palliative Care, ASL Lecce, San Cesario di Lecce, Lecce, Italy.

出版信息

Clin Transl Radiat Oncol. 2024 Dec 29;51:100905. doi: 10.1016/j.ctro.2024.100905. eCollection 2025 Mar.

Abstract

PURPOSE//OBJECTIVES: A disproportionate incidence's increase of rectal cancer in patients younger than 50 years of age. The ESMO and NCCN recommendations are not age-specific and the literature is poor and conflicting. We decided to examine patients with rectal cancer treated in our centre in the last 15 years with curative neoadjuvant radiochemotherapy comparing outcomes in the two groups under and over 55 years old.

MATERIALS/METHODS: 788 rectal cancer patients were enrolled in this monocentric retrospective observational study (523 =>55 years and 265 < 55). All patients received neoadjuvant chemoradiation treatment. R statistical software v.4.1.3 was used for the entire analysis. The outcomes were death, local recurrence, and new distant metastases. Survival analysis was performed using the Kaplan-Meier method and the Log-rank was used to compare the two groups.

RESULTS

All patients were classified in different risk groups, according to the ESMO 2017 rectal cancer clinical practice guidelines. 88 % of patients under 55 years old at the diagnosis belonged to the bad or advanced risk groups with an equal division. In patients over 55 years old, there was a clear dominance of the advanced risk class (62 % of the total). In multivariate analysis, OS and DFS decrease with increasing age and ESMO risk group. The other variables in multivariate were not significant. For Both OS, DFS and MFS, the curves separated significantly at 55 years of age, with a prevalence of metastasis development in the older group.

CONCLUSION

Elderly patients have a prevalence of advanced disease. Younger patients seem having a better OS at 3 and 5 years. ESMO risk group and age were the only variables affecting OS and DFS. Young patients have better MFS and DFS at 2 and 5 years than patients older than 55 years. The addition of oxaliplatin to fluoropyrimidine-based neoadjuvant chemotherapy resulted not significant in both groups.

摘要

目的//目标:50岁以下患者中直肠癌发病率不成比例地增加。欧洲肿瘤内科学会(ESMO)和美国国立综合癌症网络(NCCN)的建议并非针对特定年龄,且相关文献质量不高且相互矛盾。我们决定对过去15年在我们中心接受根治性新辅助放化疗的直肠癌患者进行研究,比较55岁及以上和55岁以下两组患者的治疗结果。

材料/方法:788例直肠癌患者纳入了这项单中心回顾性观察研究(523例年龄≥55岁,265例年龄<55岁)。所有患者均接受新辅助放化疗。整个分析使用R统计软件v.4.1.3。观察指标为死亡、局部复发和新发远处转移。采用Kaplan-Meier法进行生存分析,并用Log-rank检验比较两组。

结果

根据ESMO 2017年直肠癌临床实践指南,所有患者被分为不同风险组。诊断时年龄小于55岁的患者中,88%属于不良或高危风险组,两组比例相当。在55岁以上的患者中,高危风险组占明显优势(占总数的62%)。多因素分析显示,总生存期(OS)和无病生存期(DFS)随年龄和ESMO风险组的增加而降低。多因素分析中的其他变量无统计学意义。对于OS、DFS和无转移生存期(MFS),曲线在55岁时明显分开,老年组转移发生率更高。

结论

老年患者中晚期疾病更为普遍。年轻患者在3年和5年时的总生存期似乎更好。ESMO风险组和年龄是影响OS和DFS的唯一变量。年轻患者在2年和5年时的MFS和DFS比55岁以上患者更好。在两组中,基于氟嘧啶的新辅助化疗中添加奥沙利铂均无显著效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc1/11780713/8ef896897f1f/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验